Carthera

Carthera operates at the intersection of medical devices, therapeutic ultrasound and neuro-oncology. Its core differentiation is the SonoCloud implant, which is designed to temporarily open the blood-brain barrier so therapeutic molecules can reach the brain at higher concentrations. That approach addresses a major delivery constraint in brain tumors and could also support applications in neurodegenerative disease. The company is distinct from conventional drug developers because its primary asset is an implantable device and treatment-enabling platform rather than a standalone pharmaceutical. It is also distinct from non-invasive focused-ultrasound systems because SonoCloud is implanted and being developed for repeatable, localized blood-brain barrier modulation during treatment. The available comparison set does not identify distinct named competitors, so direct relative claims should be treated cautiously. Carthera’s market position is nevertheless supported by clinical-stage development, the SonoCloud-9 program, U.S. and EU orphan designations announced in 2024, and EMA expert-panel endorsement for Orphan Medical Device status in 2025. Its competitive risk remains substantial: adoption depends on clinical outcomes, neurosurgical procedures, regulatory clearance, reimbursement and partnerships with drug developers or care providers.

Carthera has followed a long clinical-development trajectory since its 2010 founding. It raised a Series A of approximately $2.2 million in 2015, followed by a $6.3 million grant in 2016 and a $10.2 million Series B in 2018. Publicly identified financing accelerated in 2020 through a $12.5 million venture round and a $2.4 million grant, both involving the European Innovation Council. The clearest financial inflection point came in 2023, when Carthera raised approximately $41.1 million on Jun 27, 2023 and another $4.8 million on Dec 11, 2023. Product and clinical milestones then became more prominent: first-patient enrollment in an ultrasound drug-delivery trial was reported in February 2024, SonoCloud-9 entered a Phase 2a trial in April 2024, and the SONOBIRD pivotal trial reached its first milestone in May 2025. The July 2025 EMA endorsement further strengthened the regulatory narrative. However, the company remains small, with an employee band of one to ten and no disclosed valuation. Its next growth phase therefore depends less on headcount expansion and more on pivotal-trial execution, regulatory progress and translation of SonoCloud into repeatable clinical workflows.